Protocol of the Swiss Longitudinal Cohort Study (SWICOS) in rural Switzerland. by Schoenenberger, Andreas et al.
Protocol of the Swiss Longitudinal
Cohort Study (SWICOS) in rural
Switzerland
Andreas W Schoenenberger,1 Franco Muggli,2 Gianfranco Parati,3,4
Augusto Gallino,5 Georg Ehret,6 Paolo M Suter,7 Renate Schoenenberger-Berzins,8
Therese J Resink,9 Paul Erne9
To cite: Schoenenberger AW,
Muggli F, Parati G, et al.
Protocol of the Swiss
Longitudinal Cohort Study
(SWICOS) in rural
Switzerland. BMJ Open
2016;6:e013280.
doi:10.1136/bmjopen-2016-
013280
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2016-
013280).
AWS, FM and PMS
contributed equally.
Received 4 July 2016
Revised 30 September 2016
Accepted 12 October 2016
For numbered affiliations see
end of article.
Correspondence to
Professor Therese J Resink;
therese-j.resink@unibas.ch
ABSTRACT
Introduction: Increased longevity and consequent
major changes in demographics and population
lifestyles necessitate new approaches to reduce the
burden of ageing-related diseases (including
cardiovascular disease) and maintain an optimal quality
of life. This study aims to examine and longitudinally
follow health status and disease risk factors in a Swiss
rural cohort, evaluating all health-related research and
practice disciplines to assure development of new
implementable and successful preventive strategies for
healthy ageing.
Methods and objectives: Small Swiss villages with
low migration rates will be selected for this study. 2
villages (Cama/Lostallo) have already been selected as
initial study sites. All residents (age ≥6 years, no upper
age limit) are eligible. The target enrolment number per
village is 300. Examinations and measurements
encompass medical history, anthropometry, cardiac
and vascular health, pulmonary function, physical
performance, nutritional, mental and emotional status,
biochemical and molecular analyses. Follow-up
examinations (identical to baseline) will be performed
after 5 and 10 years, and in 10-year intervals thereafter.
The major objective is to assess, and observe change
in, health status over time in a prospective manner.
Secondary objectives are to: (1) identify ‘hidden’
(asymptomatic and/or unrecognised) health problems
which enhance risk for chronic diseases; (2) identify
barriers to accessing healthcare and adapting health
behaviours; (3) evaluate efficacy of present preventive
strategies and recommendations; (4) evaluate
knowledge and attitude towards ongoing health
programmes and public health recommendations; (5)
monitor change and progress towards the national
health objectives; (6) formulate new preventive
strategies and recommendations based on the findings
and knowledge base of the past 10 years; (7) formulate
models for successful prevention of chronic diseases
and for healthy ageing.
Ethics and dissemination: The Ethics Committee of
Nordwest-und Zentralschweiz approved this study
(EKNZ 2014-209). It is registered at ClinicalTrials.gov
(NCT02282748). Findings will be disseminated through
scientific articles/presentations and public events.
INTRODUCTION
Life expectancy at birth in Switzerland is cur-
rently one of the highest in the world, result-
ing from a signiﬁcant rise during the 20th
century. Between 1900 and today, it has risen
from 46.2 to 80.8 for men and from 48.8 to
84.9 for women.1 The promotion of healthy,
independent and active ageing is a public
health priority since longevity is only desir-
able if accompanied by good health and
high quality of life. Ageing is associated with
development of several chronic diseases and
Strengths and limitations of this study
▪ The study is epidemiological in nature and direc-
ted towards monitoring of ageing in good health
and improving quality of life rather than extend-
ing lifespan.
▪ In addition to documentation of conventional
epidemiological parameters of cardiovascular
health, it uses contemporary technologies
including home blood pressure (BP) monitoring,
24-hour BP recordings, Audicor ECG, TensioMed
oscillometric device for BP measurement, central
BP estimate and oscillometric arterial stiffness
assessment.
▪ Establishment of a well-defined database on the
health status (including issues of mental and
physical fitness) and cardiovascular disease risk
factors of a free-living population in Switzerland
will create a basis for research in other disci-
plines such as neuropsychology, gerontology
and geriatrics.
▪ Our approach may aid other countries with com-
parable modern population and socioeconomic
profiles in designing strategies to contemporise
data on population health and to improve pre-
ventive population-based programmes.
▪ The voluntary random sampling of the registry
might generate a bias, and motivation of the par-
ticipants to come for follow-up visits cannot be
predicted.
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one particular objective in the promotion of healthy
ageing in Switzerland is improvement of strategies
aimed at primary prevention.2–5 Cardiovascular disease
(CVD), which is the leading cause of death and serious
illness in Switzerland,6 has long been the focus of
several risk factor identiﬁcation studies.
In 1948, when little was known about the general
causes of heart disease and stroke, the Framingham
Heart Study helped to contribute, in a major way, to a
better understanding of the principal risk factors for
CVD (high blood pressure, high blood cholesterol,
smoking, obesity, diabetes and physical inactivity)7–10
and the Framingham Heart Study became one of the
most renowned studies in medical history. Other studies
followed, such as the Münster Heart Study (PROCAM),
initiated in 1979 in Germany. The aim was to examine
cardiovascular risk factors and cardiovascular events in
17 437 men and 8065 women at work.11 12 Participants
were evaluated at baseline and were followed longitudin-
ally. The PROCAM cardiovascular risk score is currently
used by the Swiss Atherosclerosis Association (AGLA),13
among many other users. The Baltimore Longitudinal
Study of Aging (BLSA) is one of the longest ongoing
longitudinal studies of ageing in the world.14 The BLSA
initially focused on the physical and cognitive changes
associated with normal ageing, free of disease and later
addressed the inter-relationship between disease and
age-related changes, looking at their combined effect on
physical and cognitive function. The central BLSA ques-
tion of ‘What is aging?’ now extends to exceptional
ageing, targeting rare individuals who survive well into
their 80s with no health problems. There are no equiva-
lent studies devoted to healthy ageing or the degree of
ageing in a healthy population in Switzerland.
Switzerland has a particularly high life expectancy and
is different from other European countries with regard to
fundamental features such as its healthcare system and
health habits.15 16 Particular strengths of the healthcare
system include guaranteed access to healthcare, the
broad spectrum of beneﬁts and services covered by the
mandatory health insurance system, interest in preven-
tion and awareness of health value, and the high quality
of care provided.15 16 However, weaknesses of the system
include poor targeted management, incomplete statis-
tical and analytical bases and inadequate investment in
prevention and in early detection of diseases.15 16 In
Switzerland, a number of population-based cohort
studies have been conducted, including a study on per-
ipheral arterial disease in workers of four pharmaceutical
companies,17 the SAPALDIA study on air pollution and
lung disease in adults of eight geographic areas repre-
senting the range of environmental, meteorological and
sociodemographic conditions of Switzerland,18 and
studies that focus on epidemiology and genetic determi-
nants of cardiovascular risk factors and diseases in popu-
lations living in large cities such as Geneva (the BusSanté
study)19 and Lausanne (the CoLaus study).20 The Swiss
Kidney Project on Genes in Hypertension (SKIPOGH),21
the Bundesamt für Gesundheit (BAG) Swiss Salt Study22
and the BAG Nationales Programm Ernährung und
Bewegung (NPEB)23 are recent or ongoing cross-
sectional studies that address only restricted sets of
research questions. SAPALDIA, launched in 1991 as a
study to examine effects of air pollution on the respira-
tory and cardiovascular health in adults (aged 16–60),
was recently (2014) converted into a Swiss platform for
ageing research, with the intention of expanding the
database to include information on outcomes such as
multimorbidity, disability and functional decline, frailty,
quality of life, as well as health and social service usage,
and also to use its biobank of prospectively and longitu-
dinally sampled blood and genetic material to study bio-
logical ageing processes.24
Cohort studies that follow participants longitudinally
are important for many reasons. First, many new diag-
nostic techniques and therapeutic options have become
available and it is important to apply them at the popu-
lation level, outside of highly selective randomised trials.
Second, with increasing longevity and demographic
changes in the past decades, the elderly become increas-
ingly important for the implementation of preventive
measures. Many pathologies and risk factors have a
strong age-related component (eg, dementia, heart
failure and hypertension) and will therefore dramatically
change in their prevalence and incidence.
Consequently, new strategies for prevention and therapy
are required. Third, shifts in the risk factor distribution
are occurring such as an increase in the prevalence and
incidence of overweight and obesity in the younger
population strata despite preventive interventions to
promote a healthy lifestyle.25 26 It seems that many of
the currently applied recommendations and preventive
strategies and approaches to improve the health status in
the population are not working and cannot be imple-
mented in a sustainable manner. Fourth, new knowledge
on behavioural and neurophysiological risk factors (eg,
sleep disorders) as well as aspects of health maintenance
are still ignored in daily practice and also in risk factor
research at the population level. It is timely to assess
these factors outside of laboratory conditions. In view of
the epidemiological trends of chronic diseases and the
consequent uncontrollable burden on healthcare expen-
ditures, new preventive strategies are urgently required.
Fifth, risk for CVD varies between countries and the
results of previous studies may therefore apply to the
Swiss population only in part.2 Sixth, a key concept of
this study is to establish a well-deﬁned database on the
health status and disease risk factors (Why do certain
people get sick and others not?) of a small free-living
population in Switzerland which should be the basis for
research of other disciplines (for instance, neuropsych-
ology, gerontology, geriatrics). Applied ‘health promo-
tion research’ can only be made in a setting as
suggested in the present study.
Our study therefore aims to create, examine and
follow a population-based cohort among inhabitants of
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Switzerland, evaluating in the long term all
health-related research and practice disciplines to assure
the development of new implementable and successful
preventive strategies for healthy ageing. An important
beneﬁt of a cohort study over a trial is the ability to study
multiple risk factors and disease outcomes simultan-
eously, thus allowing for the identiﬁcation of the highest
impact preventive strategies. Such a study has a high
potential to inﬂuence national policies in many aspects
of health, health promotion and disease prevention and
ﬁnally well-being of the population and country.
METHODS AND ANALYSIS
Study design
This is a longitudinal prospective cohort study with a
population-based cross-sectional baseline examination
and long-term longitudinal follow-up.
Study objectives
The primary objective is to assess the health status, with
particular attention to cardiovascular health, and
observe the change in health status in a representative
sample of the Swiss population over time in a prospect-
ive manner.
Secondary objectives are: (1) to identify ‘hidden’
(asymptomatic and/or unrecognised) health problems
(including health behaviours and cognitive factors)
which enhance the risk for chronic diseases (eg, CVD,
ageing-related diseases, dementia, inter alia); (2) to
identify and determine barriers to accessing healthcare
and adapting health behaviours; (3) to evaluate the efﬁ-
cacy of the present preventive strategies and recommen-
dations; (4) to evaluate the knowledge and attitude
towards ongoing health programmes and public health
recommendations; (5) to monitor the change and pro-
gress towards the national health objectives;27 (6) to for-
mulate new preventive strategies and recommendations
based on the ﬁndings and the knowledge base of the
past 10 years; (7) to formulate and develop models for
successful prevention of chronic diseases and for healthy
ageing.
Achievement of these objectives should lead to devel-
opment of a dynamic research team and provide scien-
tiﬁc knowledge to be considered in the frame of speciﬁc
expertise of the participating investigators.
Specific study questions
The main questions under investigation are:
1. What is the health status and, in particular, the car-
diovascular health status of a Swiss population-based
cohort and what are typical ﬁndings in a Swiss
population-based cohort using new diagnostic
methods and techniques?
2. What are the dynamics of changes in the health
status over time and what are the determinants of
and predictors for a negative or positive change in
the health status?
3. What are the factors inﬂuencing healthy ageing?
4. What are the current national standards (eg, for
height, weight, blood pressure, cholesterol levels)
and what are the age-related changes of these
standards?
Study sites
Two neighbouring villages in Southern Switzerland,
Cama and Lostallo (Canton Graubünden), have been
selected as initial study sites based on the following con-
siderations: Swiss population, typical age structure and
sex distribution, low migration over time, variety of socio-
economic factors, number of inhabitants sufﬁcient
according to sample size calculation, support from local
political and medical authorities and favourable infra-
structure for this study. It is planned to include further
study sites in Switzerland based on the same criteria.
Participants
Recruitment procedure: First, the municipal authorities and
the general practitioners of the selected regions are
informed about the project. Second, local nurses and
physician assistants, followed by local representatives of
the press and media, are contacted and informed.
Information ﬂyers are distributed and the study applica-
tion is made available on the local website. Information
sessions for the village population and door-to-door
explanatory visits are conducted, and positive feedback
of participants is estimated. To correct for volunteer
bias, the recruitment is currently based on ‘randomised
inclusion’. A part of the future participants will ﬁrst be
randomised through a computerised system linked to
documents held in the ofﬁces of their general practi-
tioner and then invited to participate. The information
and education campaign in the ﬁrst participating village
was initiated in October 2014. Recruitment began in
March 2015 and will proceed until at least the targeted
enrolment number (300) per village is reached.
Eligibility: All residents of the selected villages are eli-
gible and will be invited to participate in the study. As
described above, participation is based on voluntary
response sampling of the village population.
Inclusion criteria: Age ≥6 years (no upper age limit),
for voluntary blood sample age ≥18 years, willingness to
participate in long-term study, written informed consent
(signed by parents for participants ≥6 and <14 years).
Exclusion criteria: There are no exclusion criteria.
Pregnancy is not an exclusion criterion for participation
in this study. However, if pregnancy is known, the visit is
postponed for an examination date after delivery,
because important measurements in the context of this
study may be biased by pregnancy. In patients with
mental illness and unable to provide informed consent,
consent is obtained from a proxy.
Examinations and measurements
All examinations of study participants will be performed
at regular time intervals. The investigators perform the
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baseline examinations at designated locations in the spe-
ciﬁed study sites. The visits, lasting ∼90 min, are per-
formed in clinic, and the organisation screens four
different individuals per given examination day. After
the baseline examination of a study participant,
follow-up examinations will be performed after 5,
10 years and in 10-year intervals thereafter. The intervals
might vary according to other research questions. The
follow-up examinations are identical to the baseline
examination. In addition to these examinations, every
participant will be contacted annually (by mail or tele-
phone when possible) with a request to complete a
short questionnaire (focusing on history, residence and
other study issues).
The examination has two major components:
1. Health interview survey using different
questionnaires
This component of the study embraces a thorough
assessment of the health and disease status of the partici-
pants using modern and standardised interview-based
techniques (self-administered, partially computer-
assisted, interviews and structured interviews). The self-
administered health survey questionnaire (in the Italian
language) is extensive: to illustrate the nature of the
assessment, we present the speciﬁc queries pertaining to
symptoms, respiratory problems, cardiac problems,
general aches and pains, medical history, surgical inter-
ventions, and medications as online supplementary
information.
2. Clinical and biochemical assessment
This component of the study is complementary to the
interview component and involves a series of clinical,
biochemical and molecular tests.
Clinical tests encompass anthropometric measure-
ments, evaluation of the cardiovascular system (ie, blood
pressure and cardiac function) and lung function, assess-
ment of general cognitive functions, physical perform-
ance, nutritional status and emotional status.
Biochemical and molecular tests comprise the follow-
ing: (1) urine samples: proteinuria, glucosuria, erythrocy-
turia; (2) blood samples: red and white cell count,
sodium, potassium, creatinine, aspartate, transaminase,
albumin, lipids, glucose, ferritin, total iron binding cap-
acity, thyroid stimulating hormone; (c) snap-frozen serum
samples: systemic genomic, proteomic and metabolomic
analyses.
Each participant should fully undergo both examin-
ation components (except blood sampling in partici-
pants ≥6 and <18 years). If the biochemical and/or
molecular assessments are refused, the interview survey
should be performed whenever possible. Table 1 sum-
marises all examinations and measurements performed
in the context of this study.
After the examination, individual counselling is
offered to each participant. In participants who wish
to receive counselling, the ﬁndings of the examination
are explained to the participant by one of the investi-
gating physicians and recommendations for prevention
are provided. All participants wishing to receive a
written report are sent a short summary report of the
ﬁndings.
Data collection, validation and management
The physician checks the completeness of self-
administered questionnaires on the arrival of the partici-
pant, unclear answers are discussed directly and the
physician makes corrections in the presence, and with
the consent, of the participant. Results of measurements
are documented at the study site on a paper-based ques-
tionnaire. After the examination, the questionnaires are
collected and subjected to a plausibility check-up by the
physician and the study nurse (ie, a four-eye principle).
If applicable, questionnaires are formally corrected by
the physician with documentation of corrections. The
participant’s name and address (page 1 of question-
naire) are entered in one electronic database and all
other information from the questionnaire is entered in
another anonymous electronic database. Both databases
may be linked together with the use of a unique identi-
ﬁer allowing identiﬁcation of the study participant,
which is important for the planned cross-sectional
follow-up examinations, and the key is kept separately.
All data from the questionnaires are entered in the data-
bases using two-pass veriﬁcation. After data entry, data
are checked for completeness and plausibility by the
data manager. Incomplete or implausible data are
amended by the data manager who is obliged to proto-
col all changes in the database.
The databases will be encrypted using passwords and
stored on one computer. The computer is only access-
ible with another password. Encrypted backups on two
external hard disks are periodically made from both
databases. Both hard disks are stored at different loca-
tions. As an additional measure against data loss, ques-
tionnaires will be stored on paper in a safe place.
Primary data users are those who designed and devel-
oped the study and who collected the ﬁrst cross-sectional
data assessment. However, this initial cross-sectional
study and data collection will be the basis for a long-term
study with different external co-investigators in different
biomedical ﬁelds. Collaborations with other researchers
in the ﬁeld will be promoted.
Data protection
In the context of this study, sensitive health data are
assessed. Other sensitive data (eg, religious, political,
social security or administrative data) are not assessed.
Data are handled according to the European Union
(EU) Data Protection Directive.28
Statistical considerations
Sample size calculation: To detect a clinically relevant
increase in blood pressure from baseline 130 to
135 mm Hg at follow-up, 32 participants are needed
(assumptions: SD 10 mm Hg for blood pressure values,
signiﬁcance level 5% and power 80%). Similarly, to
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Table 1 Summary table of examinations and measurements
Domain Parameter Instrument/technique
Assessing
person
Time
needed
(minutes)
Administrative/general/
social
Name Self-administered
questionnaire
Participant 10
Address
Phone number
Birth date (dd/mm/yy, time of
day)
Sex
Birth weight (based on birth
record)
Place of origin
Living situation
Education
Occupation
Means of transport used
Social ties
Immunisation status
Medical history Symptoms (NYHA-class, AP
CCS, pain)
Self-administered
questionnaire (controlling
by physician)
Participant/
physician
10
Cardiovascular risk factors
Previous cardiovascular events
Previous surgical interventions
Drugs (prescribed and
over-the-counter)
Alcohol, smoking
Falls history
Sleep disorders
Anthropometry Body weight Balance (measurement in
underwear)
Study nurse 10
Body height Measure
Circumference of upper and
lower extremities
Tape measure
Circumference of thighs, waist
and hip
Tape measure
Skinfold thickness (trunk/
extremities)
Caliper (Harpenden)
Body composition Segmental bio-impedance
(Tanita SC-240)
Continued
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Table 1 Continued
Domain Parameter Instrument/technique
Assessing
person
Time
needed
(minutes)
Cardiovascular system Resting blood pressure/heart rate
(sitting position and 1–3 min after
standing up)
Oscillometric device
(Omron 705IT)31
Study nurse/
physician
25
Central blood pressure and pulse
wave velocity
Oscillometric device
(TensioMed
Arteriograph)32
Home blood pressure
measurement
Oscillometric device
(Takeda UA-651)33
Ambulatory blood pressure
measurement
Oscillometric device
(Takeda TM-2430)34
Heart rate, PQ, QRS, QT, ST,Q Normal ECG (Schiller
AT02)
Pulse wave analysis Tonometer (PulsePen,
Diatecne)35
Heart sounds, electromechanical
activation time
Audicor36 37 Holter
recording (24 hours)
Brain Vision Jaeger test38 Study nurse 20
Hearing Whisper test39
Cognition (participants
≥50 years)
MMSE40
Verbal fluency
Clock drawing test41
Executive function Trail making test B42
Reaction time Computer-based tool
Lung Pulmonary function Peak flow
O2 saturation
Lung function (MIR
Spirobank)43
Study nurse 2
General physical
performance
Physical activity Physical activity
questionnaire
Study nurse/
physician
12
Walking speed 2 minute walking test44
Arm strength Handgrip test45
Leg strength Chair stand test46
Balance 4-stage balance test47
ADL Basic and instrumental
ADL48 49
Continued
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Table 1 Continued
Domain Parameter Instrument/technique
Assessing
person
Time
needed
(minutes)
Nutritional status Weight loss Self-report question Participant/
physician
3
Food frequency Food frequency questionnaire
Consumer behaviour
and food security
Consumer behaviour/food
security questions
Emotional status Depression (participants
≥18 years)
Depression screening
questionnaire50
Physician 10
Anxiety (participants ≥18 years) Anxiety screening
questionnaire50
Self-perceived health
(participants ≥18 years)
Blood sample (only
participants ≥18 years,
voluntary)
Red and white cell count Study nurse 5
Sodium, potassium
Creatinine Blood sample in fasting state, measurement in
validated laboratoryAspartate, transaminase,
albumin
lipids, glucose/HbA1c
Iron status (ferritin, TIBC)
TSH
Metabolomics, proteomics,
genomics
Blood sample (50 mL) in heparin-free tube,
processed immediately for serum collection,
aliquoting and storage in RNase-free cryotubes in
a sample bank at −80° for later analysis. All
necessary preanalytical precautions will be
implemented.
Urine sample (only
participants ≥18 years,
voluntary)
Proteinuria Urine sample with test strip Study nurse 3
Glucosuria
Erythrocyturia
ADL, activities of daily living; AP CCS, Canadian Cardiovascular Society grading of angina pectoris; HbA1c, glycated haemoglobin; NYHA, New York Heart Association; MMSE, Mini Mental
State Examination; TIBC, total iron binding capacity; TSH, thyroid stimulating hormone.
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detect a relevant change of 1 Mini Mental State
Examination (MMSE) point in the cognitive function
between baseline and follow-up, 26 participants are
needed (assumptions: SD 1.3 for the difference between
baseline and follow-up,17 signiﬁcance level 5%, and
power 80%). To detect a minimal clinically relevant
change in the 2 min gait-speed test, 63 participants are
needed (assumptions: SD 20.6 s for the difference
between baseline and follow-up,18 signiﬁcance level 5%,
and power 80%). Based on the rule of 10 events per
variable in logistic and Cox regression, a predictive
model for 10-year mortality involving ﬁve predictive vari-
ables requires 250 participants under the assumptions of
a mortality rate of 2% per year.29 To evaluate the effect
of a binary variable with an SD of 0.5 (eg, presence or
absence of arterial hypertension) on an outcome (eg,
mortality, myocardial infarction) in Cox proportional
hazards models, assuming an HR of 0.7 as the effect
size, 247 participants are required (further assumptions:
signiﬁcance level 5% and power 80%).30 Under the
further assumption of a lost to follow-up quote of 10%,
it is aimed to recruit ∼300 study participants per village.
The recruitment quote is expected to ∼50% of all
invited individuals. Each of the selected study sites has a
population of at least 600 inhabitants.
Statistical analysis: Statistical analyses will be performed
in collaboration with independent Swiss institutions.
Analysing institutions will be selected according to the
study question under investigation and the collaborating
investigators. Statistical methods will be selected accord-
ing to the study question under investigation. For cross-
sectional analyses, means or medians will be reported
according to the distribution of the continuous variable;
proportions will be used for categorical variables.
Hypothesis testing will be done using t-test for normally
distributed continuous variables and non-parametric
tests for non-normally distributed continuous variables;
χ2 testing will be used for categorical variables. Linear
and/or logistic regression models with or without adjust-
ment for potential confounders will be used whenever
appropriate. For the analysis of longitudinal data, sur-
vival analysis including Kaplan-Meier curves as well as
Cox proportional-hazards models will be used whenever
appropriate.
Outcomes
According to the design and questions of this study, a
great variety of outcomes will be analysed. In a ﬁrst step,
data from baseline evaluation will be analysed. The main
outcome of this study is the assessment of mortality rate
in the follow-up. However, cross-sectional outcomes at
baseline and longitudinal outcomes at follow-up will be
separately assessed as follows:
1. Cross-sectional outcomes at baseline:
▸ Prevalence of disorders in the Swiss population
(eg, cardiovascular risk factors, orthostatic hypo-
tension, mental and/or emotional disorders,
frailty and/or disability, or sleep disorders).
▸ Ranges of central and 24-hour peripheral blood
pressure.
▸ Associations between different disorders (eg, asso-
ciations of mental and/or emotional disorders
with blood pressure and tonometrically assessed
arterial wall properties).
2. Longitudinal outcomes at follow-up:
▸ Mortality (eg, overall mortality, cardiovascular
mortality, cancer mortality).
▸ Morbidity (eg, non-fatal myocardial infarction,
non-fatal stroke, renal failure).
▸ Functional decline (eg, frailty, disability, cognitive
decline, nursing home admission).
Ethical aspects
Participants will be required to give informed consent
for study participation, which includes permission to
store a blood sample for future research; to link registries
containing data relating to the participant’s health (eg,
pharmacy, hospital, general practitioner); and ﬁnally to
link with mortality registries where applicable. The
ethical committee and regulatory authorities will receive
interim reports and be informed about study stop/end
in agreement with local requirements. The study will be
carried out in accordance with the protocol and with
principles enunciated in the current version of the
Declaration of Helsinki, the guidelines of Good Clinical
Practice (GCP) issued by the International Conference
on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH),
the Swiss Law and Swiss regulatory authority’s
requirements.
Dissemination
The ﬁndings of the study will be disseminated through
peer-reviewed journals, national and international con-
ference presentations and public events involving the
local administrations of the villages where the study par-
ticipants are resident. Furthermore, data will be pre-
sented to Swiss policymakers and healthcare workers to
improve preventive strategies to combat CVD and to
promote healthy ageing.
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